Quick Dispatch:
Your surmount tirzepatide Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount tirzepatide Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 ships.
Need Help?
Questions about surmount tirzepatide Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount tirzepatide Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 in your area.
01200-X/asset/429e6fd1-61d1-402a-91a5-b2ec86b1b878/main.assets/gr2_lrg.jpg "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial")
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
21.56
SURMOUNT-1: In an RCT, adults with obesity treated with weekly tirzepatide had major weight loss over 72 weeks. #ADA2022 https://t.co/X2RrvYxzsV
25.17
Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Trial
29.22
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary:
23.90
Effect of tirzepatide in SURMOUNT-1 trial. (BMI: body mass index; CI:
20.42
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity
21.31
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
29.63
